In recent years, the Chinese government has elevated the digital economy to an important position in national strategy. With the support and guidance of national policies, pharmaceutical companies are actively seeking change amidst the tide of digital and intelligent development. Multiple factors such as trends of the times, fierce market competition, and the company's own development strategies are driving the digital and intelligent transformation of the entire value chain of the pharmaceutical industry.
On September 5th, at the Pharmaceutical Industry Digitalization Summit (PHDI 2023), Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') officially released the '2023 China Pharmaceutical Industry Digitalization Development Blue Book' (hereinafter referred to as the 'Blue Book'). The report aims to detail the application benefits of digitalization technologies, sort out the driving factors behind the industry's rapid transformation, deeply analyze the difficulties and challenges currently faced by China's pharmaceutical industry in digitalization transformation, and jointly focus with the industry on advanced enterprises that have demonstrative promotion significance and practical value. It comprehensively explores feasible paths and future development trends for the digitalization transformation of the pharmaceutical industry.
